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Introduction
The incidence of esophageal adenocarcinoma, a deadly cancer,
is escalating in comparison to other cancers (colon, lung, and
breast) (Patel & Gyawali, 2019). While providing surgical care
for patients undergoing a transthoracic esophagectomy on a
routine basis, there were significant trends amongst the patient
population: history of gastroesophageal reflux disease, Barrett’s
Esophagus diagnosis, patient demographics and social history.
As a nurse providing care for patients with advanced disease,
requiring invasive surgery, it was very appealing to understand
the disease process and management of Barrett’s Esophagus.
The exact pathogenesis of Barrett’s Esophagus to esophageal
cancer remains uncertain, and there are limited strategies for
early detection and prevention of esophageal cancer. It is with
sincere appreciation to care for this patient population and
sincere determination to educate about the risks associated
with Barrett’s Esophagus.

•

•

•

•

Significance of Pathophysiology

The use of biomarkers and other
screening measures may improve the
cost-effectiveness of Barrett’s
esophagus screening, but are currently
being developed with limited data
(Patel & Gyawali, 2019).
The extent of tissue changes and
dysplasia drive surveillance and
treatment.

•

•

•

Pathogenesis
•

Background

Barrett’s Esophagus is a condition in which stratified
squamous epithelial cells in the distal esophagus are
replaced by metaplastic columnar epithelium
with/without goblet cells (Clermont & Falk, 2018).
Cellular changes in the distal esophagus is a result of
exposure to chronic reflux of acid and bile (Eluri &
Shaheen, 2017).
Barrett’s Esophagus is a precursor to esophageal
adenocarcinoma.

Who is at risk?
•

Diagnosis & Screening cont’d:
•

Increased age (over 50), Caucasian males, with central
obesity, and an underlying history of smoking, and/or
chronic gastroesophageal reflux disease (GERD) (Eluri &
Shahen, 2017; Patel & Gyawali, 2019).
GERD can be present with or without heartburn or with
atypical symptoms such as: chest pain, cough, sore throat,
and laryngitis. What’s more, symptoms diminish or
“improve” as the disease develops (Patel & Gyawali, 2019).

Implications for Nursing Care
•
•
("Johns Hopkins Department of Pathology: Barrett's Esophagus", 2020 )

•

•
•

•
•

•

The progressive multi-step cellular
changes (metaplasia to dysplasia, to
carcinoma) in the distal esophagus is
from chronic reflux of acid and bile.
The precise pathogenesis of Barrett’s
Esophagus remains uncertain.
The esophagus is lined with stratified
squamous epithelial cells which are
then replaced by metaplastic
columnar epithelium.
Not all patient’s with a diagnosis of
Barrett’s Esophagus will progress to
esophageal cancer.
Those diagnosed with esophageal
cancer may not have a history of
esophageal dysplasia.

•

•

•

•

•

•

Diagnosing and screening for Barrett’s is challenging and
complex. The preferred screening method for those with
associated risk factors for mucosal changes and dysplasia is
an upper endoscopy by a gastroenterologist. An upper
endoscopy is preferred, as they are surveying tissue at the
distal esophagus (Patel & Gyawali, 2019).
Gastroenterologists utilize the Prague Classification system
to standardize mucosal changes in suspected tissue and are
required to provide precise tissue sampling.
Endoscopic recognition of anatomical landmarks can be
very challenging to identify due to esophagitis, respiration
and peristalsis. (Clermont & Falk, 2018).
Tissue sampling is reviewed and confirmed by two
pathologists for diagnosis of Barrett’s Esophagus, low-grade
dysplasia and high-grade dysplasia (Clermont & Falk,
2018).

Identify and educate those at risk: Caucasian males, over 50 years of age,
with central obesity, GERD, familial and tobacco use history.
Provide resources and education for dietary changes and smoking
cessation.
Manage GERD symptoms with a once-daily dose of a proton pump
inhibitor (Eluri & Shaheen, 2017).
Know that nonsteroidal anti-inflammatory drugs (NSAIDs), for those
with Barrett’s Esophagus, reduce progression of esophageal
adenocarcinoma by 30% (Eluri & Shaheen, 2017). Keep in mind the
bleeding risk with NSAIDs; does the benefit outweigh the risk?
Screening is important, but is not cost effective to screen those that
aren’t at risk. Consider an upper GI study during routine colonoscopies
for at-risk patients.
Consult and refer patients to a gastroenterologist to help guide and
manage the disease.

Conclusion
Barrett’s Esophagus occurs in about 15% of those with GERD,
and not all cases of Barrett’s progress to esophageal carcinoma
(Eluri & Shaheen, 2017). The overall goal is to identify those at
risk to optimize screening and surveillance, because the
prevalence of esophageal carcinoma is rising. Barrett’s is
complex to diagnose and screen, but there are multiple
treatment modalities available. Identifying those at risk and
minimizing acid reflux are the beginning stages of prevention.
Current research is focused on the pathogenesis of Barrett’s,
surveillance methods, and eradication therapies. It is with
great hope that further research will promote screening in atrisk patient populations, similarly to other prevalent cancers
like breast, colon and lung.

Diagnosis & Screening
•

Researchers know that the epithelium in the distal esophagus changes, but
the original cause of metaplasia and the process in which cells transform to
cancer remain unknown. For example, acid reflux contributes to the
pathogenesis of Barrett’s, the question remains, does acid reflux cause a
chemical injury to the cells, or do the cells alter due to repeated
inflammation?
A patient can be diagnosed with esophageal cancer without any history of
Barrett’s Esophagus. What’s more, a patient with Barrett’s can still progress
to esophageal cancer despite having no history of dysplasia (Eluri &
Shaheen, 2017).
The uncertainty of disease pathogenesis contributes to difficulty identifying
which patients to screen for disease. Not only does the deficit in
understanding pathogenesis contribute to understanding those at risk for
Barrett’s, it also makes it difficult to predict which patients will progress to
cancer (Inadomi et al., 2018).

Images above and below: ("Johns Hopkins Department of
Pathology: Barrett's Esophagus", 2020)
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